https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18

 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

https://kurosbio.com/  

8952 Schlieren, Wagistrasse 25

 +41 (0)44 733 4747

Our focus is on revolutionizing the field of orthobiologics by developing bone grafts that deliver both targeted and controlled bone healing.

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor  

8952 Schlieren, Zürcherstrasse 39D

 +41 58 851 80 00

Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.

http://www.insphero.com  

8952 Schlieren, Wagistrasse 27

 +41 44 515049-0
 info@insphero.com

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company currently counts all of the top ten global pharmaceutical and cosmetics companies as customers and is helping them to implement its patented microtissue technology in their development work-flow.

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

http://www.lmtbio.com  

8952 Schlieren, Grabenstrasse 3

 +41 44 733 85 85
 info@lmtbio.com

LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation bioconjugate vaccines using glycoengineering and protein glycosylation techniques previously developed by GlycoVaxyn and now owned by GSK. It was founded as a spin-off of GlycoVaxyn AG, which was acquired by GSK in February 2015 following a two-year collaboration. LimmaTech is developing vaccines exclusively for GSK and actively explores applications of glycoengineering and protein glycosylation technology in other fields.

http://www.bio-technopark.ch/  

8952 Schlieren, Wagistrasse 23

 +41 76 336 99 44
 mario.jenni@bio-technopark.ch

The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.